Multitracer PET/CT with [18F]Fluorodeoxiglucose and [18F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study

Initial staging of patients diagnosed with multiple myeloma (MM) can lead to negative results using conventional diagnostic imaging workup, including [18F]Fluorodesoxiglucose ([18F]FDG) PET/CT. The aim of this prospective pilot study was to evaluate the diagnostic efficacy of [18F]Fluorocholine ([18F]FCH) PET/CT in the initial staging of MM patients who were candidates for autologous bone marrow transplant. Materials and Methods: The inclusion criteria of our study were: (a) patients diagnosed with MM; (b) candidates for autologous bone marrow transplant (AT); and (c) studied with [18F]FCH PET/CT and [18F]FDG PET/CT for initial staging less than 4 weeks apart. Imaging analysis included the presence of: bone marrow infiltration, focal bone lesions, and para-medullary or extra-medullary disease, according to the proposed IMPeTus criteria. The analysis was performed per lesion, per patient, and per location. Results: The study population included ten patients. Globally, [18F]FCH PET/CT showed bone marrow uptake in all the patients and visualised 16 more focal lesions than [18F]FDG PET/CT. One patient presented a plasmacytoma, detected by both tracers. Extra-medullary and para-medullary disease was identified with different degrees of uptake by both tracers. In summary, [18F]FCH PET seemed to be superior to [18F]FDG PET/CT in detecting focal bone lesions. SUVmax values were slightly higher in [18F]FCH PET/CT than in [18F]FDG PET/CT. Conclusions: Taking into account the small study population, according to our results, [18F]FCH PET/CT could be a useful tool for staging MM patients.

[1]  S. Fanti,et al.  Are We Approaching a Change in Paradigm in PET/CT Imaging of Solid Gastrointestinal (or Digestive) Tract Tumors With the Clinical Application of FAPI Imaging? , 2023, Clinical nuclear medicine.

[2]  S. Fanti,et al.  The Concept of Strength Through Synergy Applied to the Search of Powerful Prognostic Biomarkers in Gastroesophageal Cancer: An Example Based on Combining Clinicopathological Parameters, Imaging-Derived Sarcopenia Measurements, and Radiomic Features. , 2022, Clinical nuclear medicine.

[3]  A. Alavi,et al.  18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma. , 2022, PET clinics.

[4]  S. Fanti,et al.  New Biomarkers With Prognostic Impact Based on Multitracer PET/CT Imaging in Neuroendocrine Neoplasms: The Light Leading Out of the Darkness in Challenging Tumors. , 2022, Clinical nuclear medicine.

[5]  H. Goldschmidt,et al.  The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs) , 2021, EJNMMI Research.

[6]  D. Rubello,et al.  Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma , 2021, Clinical nuclear medicine.

[7]  G. Martinelli,et al.  PET/CT in Multiple Myeloma: Beyond FDG , 2021, Frontiers in Oncology.

[8]  E. Hindié,et al.  Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial , 2020, JMIR research protocols.

[9]  E. Hindié,et al.  Choline PET/CT in Multiple Myeloma , 2020, Cancers.

[10]  Gary A Ulaner,et al.  CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. , 2020, Radiology.

[11]  A. Buck,et al.  18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers , 2020, Cancers.

[12]  Alberto Costa,et al.  ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. , 2020, Critical reviews in oncology/hematology.

[13]  H. Goldschmidt,et al.  Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma , 2019, Molecules.

[14]  W. Oyen,et al.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  H. Goldschmidt,et al.  International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. , 2019, The Lancet. Oncology.

[16]  S. Samnick,et al.  Comparison of 11C-Choline and 11C-Methionine-PET/CT in Multiple Myeloma , 2019, Nuklearmedizin.

[17]  A. Rosenwald,et al.  Hexokinase-2 Expression in 11C-Methionine–Positive, 18F-FDG–Negative Multiple Myeloma , 2018, The Journal of Nuclear Medicine.

[18]  I. Špička,et al.  Is fluorine-18-fluorocholine PET/CT suitable for the detection of skeletal involvement of multiple myeloma? , 2018, Hellenic journal of nuclear medicine.

[19]  C. Nanni,et al.  Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  C. Cicciò,et al.  PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. , 2017, Nuclear medicine and biology.

[21]  Caleb K. Stein,et al.  Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. , 2017, Blood.

[22]  Bart Barlogie,et al.  Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. , 2017, The Lancet. Oncology.

[23]  M. Mohty,et al.  18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Michael Lassmann,et al.  First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease , 2016, The Journal of Nuclear Medicine.

[25]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[27]  A. Massaro,et al.  New Acquisition Protocol of 18F-Choline PET/CT in Prostate Cancer Patients: Review of the Literature about Methodology and Proposal of Standardization , 2014, BioMed research international.

[28]  Sirong Chen,et al.  11C-Acetate PET/CT for Metabolic Characterization of Multiple Myeloma: A Comparative Study with 18F-FDG PET/CT , 2014, The Journal of Nuclear Medicine.

[29]  R. Boellaard,et al.  Optimized dose regimen for whole-body FDG-PET imaging , 2013, EJNMMI Research.

[30]  K. Togashi,et al.  Clinical value of 11C-methionine PET/CT in patients with plasma cell malignancy: comparison with 18F-FDG PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  B. Barlogie,et al.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents , 2012, Haematologica.

[32]  Ji-An Liang,et al.  FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma: A Systematic Review and Meta-analysis , 2012, Clinical nuclear medicine.

[33]  Virginie Huchet,et al.  Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of 18F-Fluorocholine and 18F-FDG in Patients with Cirrhosis or Chronic Liver Disease , 2010, The Journal of Nuclear Medicine.

[34]  Orazio Schillaci,et al.  18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer , 2010, Nuclear medicine communications.

[35]  Wim J. G. Oyen,et al.  Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma , 2009, Annals of Hematology.

[36]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[37]  V. Ambrosini,et al.  11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma , 2007, World journal of surgical oncology.

[38]  V. Ambrosini,et al.  Incidental finding of an 11C-choline PET-positive solitary plasmacytoma lesion , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[40]  Hyun Woo Kwon,et al.  Incidental finding of an 11C-acetate PET-positive multiple myeloma , 2010, Annals of nuclear medicine.